



CIF A-18.758.300  
Avda de la Innovación, n 1  
Edificio BIC (Ofic 211)  
P. T. de Ciencias de la Salud  
18100 Armilla (Granada)  
Tel: 958 750 598

Mercado Alternativo Bursátil  
Plaza de la Lealtad, 1  
28014 MADRID

Granada 25 August 2015

### **RELEVANT FACT OF NEURON BIO, S.A.**

Dear Sirs,

In compliance with the provisions of the MAB circular 9/2010 on information to be provided by companies in expansion integrated in the MAB, we hereby puts in knowledge the following information on Neuron Bio, S.A. (hereinafter "NEURON BIO" or the "Company").

The Japanese Patent Office (JPO) granted to Neuron Bio the patent ""Neuroprotective, hypocholesterolemic and antiepileptic compound", published with number JP 5759448 B2.

The patent protects the chemical entity NST0037 and its use for the prevention and treatment of neurodegenerative diseases, cognitive impairment and pathologic processes related to age. The compound has been developed by Neuron Bio based on its projects regarding the search of neuroprotective statins that began in January 2007.

The patent application was filed in October 2009 and has been granted by the European Patent Office and by the Japanese Patent Office.

We remain at your disposal for any clarification you consider appropriate.

Press release is enclosed.

Fernando Valdivieso Amate  
Chairman of the Board of Directors



CIF A-18.758.300  
Avda de la Innovación, n 1  
Edificio BIC (Ofic 211)  
P. T. de Ciencias de la Salud  
18100 Armilla (Granada)  
Tel: 958 750 598

## Press release

### Neuron Bio patents its neuroprotective compound in Japan

- Last year the company was granted with the European patent to protect its compound NST0037. Granada, 25 August 2015. The Japanese Patent Office (JPO) granted to Neuron Bio the patent ““Neuroprotective, hypocholesterolemic and antiepileptic compound”, which protects the molecule NST0037 as product and as use for the prevention and treatment of various pathologies of the Central Nervous System among of them the Alzheimer’s disease. This chemical entity is a molecule property of Neuron Bio that is in the most advanced stage of its portfolio.

The president of the Company, Fernando Valdivieso is very pleased about the news, “To date we have had achieved to progress in the European market; this new patent opens the door to the Asian market and positions the company in a strategic framework for our future commercial transactions, since Japan is one of the seven biggest pharmaceutical markets.”

The compound has been developed by Neuron Bio based on its projects regarding the search of neuroprotective statins that began in January 2007. The patent application was filed in October 2009 and has been granted by the European Patent Office and by the Japanese Patent Office.

The patented compound is a new chemical entity derived from the simvastatin that offers improved effects to prevent neurodegenerative processes related to the Alzheimer’s disease and other neurodegenerative diseases associated with the age and with no cure currently. It might also be useful to treat different diseases of the Central Nervous System.